# DiaMedica Therapeutics Inc. (DMAC)

> Source: Nexqual · https://nexqual.com/DMAC · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, DiaMedica Therapeutics Inc. (DMAC), nexqual.com/DMAC" · informational, not investment advice.

**Price:** USD 8.63 (-0.69% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 8.69 · day 8.51–8.95 · 52w 5.25–10.42 · market cap $465M · NCM

## Key facts
- 1 of 80 tracked superinvestors hold DMAC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 15.5 (range 11–25).
- Total return with dividends: 1Y +27.7% vs S&P 500 +14.9%; 5Y +114.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.21, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M | -$39.2M |
| Net income | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M | -$37.5M |
| EPS (diluted) | -$0.65 | — | — | — | — | — |
| Free cash flow | -$12.3M | -$11.6M | -$18.8M | -$22.1M | -$29.1M | -$31.5M |
| Cash + short-term investments | $45.1M | $33.5M | $52.9M | $44.1M | $59.9M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 12.1x · FCF yield -6.78% · Earnings yield -8.07%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold DMAC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Leon Cooperman | Omega Family Office | 0.68% | $24.3M | Added +70.8% |

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 15.5 (low 11, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | HC Wainwright & Co. | Reiterated | Buy | $12 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +27.7% | +114.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +27.8% | +16.5% |
| Volatility (annualized) | 57.1% | 71.2% |
| Max drawdown | -43.2% (Dec 2025→Jun 2026) | -75.7% (Nov 2021→Nov 2022) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/DMAC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-10)

- "Detailed Part 1a results, including pharmacokinetic and pharmacodynamic analyses, are expected to be presented at an upcoming medical conference and submitted for publication."
- "DiaMedica is working with sites in Canada and expects to dose its first patient in the fourth quarter of 2026, and is also preparing to expand the study to the United Kingdom later this year, subject to regulatory authorization and site readiness. ● U.S."
- "Based on its current plans, the Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations through 2027. ● Cash Flows - Net cash used in operating activities for the six months ended June 30, 2026 was $17.2 million compared to $14.7 million for the same period in 2025."
- "The Company expects G&A expenses to remain relatively steady in future periods compared to recent prior periods. ● Net Loss – Net losses were $10.1 million and $20.2 million for the three and six months ended June 30, 2026, respectively, up from $7.7 million and $15.4 million for the three and six months ended June 30, 2025, respectively."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.21 | $-0.21 | -2.4% | $0 | 4 |
| Next quarter (ends 2026-12-31) | $-0.22 | $-0.23 | -1.1% | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-0.81 | $-0.83 | -2.1% | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-0.75 | $-0.88 | -15.1% | $0 | 4 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-11): ±29.7%; last 8 reports averaged ±9.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 134.4% | ±29.7% |
| 2027-01-15 | 84 | 90.6% | ±47.9% |
| 2027-04-16 | 175 | 100.1% | ±50.7% |